Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St futures rebound as oil retreats, investors weigh US-Iran tensions
- Oil prices fall as markets weigh impact of US strikes on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Revance Therapeutics (RVNC) Misses Q4 EPS by 1c
February 24, 2020 4:34 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.99), $0.01 worse than the analyst estimate of ($0.98).
With the FDAs recent acceptance of our BLA submission for DAXI in glabellar lines, and the announcement of our distribution agreement for TEOXANEs RHA® technology, Revance has constructed an exceptional start to what we believe will be a transformational year for the... More
